Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672913 | 0.78 | NPC1 (0.36) | KDM4ENPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL1922451 | 0.73 | HTT (0.33) | KDM4ENPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL2117455 | 0.67 | KMT2A (0.32) | — | |
| SCHEMBL24108204 | 0.67 | TSHR (0.37) | NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL17652128 | 0.67 | NPC1 (0.50) | NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL28892371 | 0.67 | NPC1 (0.32) | NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL11920281 | 0.66 | HTT (0.40) | KDM4EGAANPC1HTTRAB9A | |
| SCHEMBL2117963 | 0.65 | — | — | |
| SCHEMBL2116841 | 0.65 | KDM4E (0.40) | KDM4EGAANPC1HTTRAB9A | |
| SCHEMBL3678234 | 0.65 | MEN1 (0.39) | KDM4ENPC1HTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101646657-B | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL CO JP | 2012-08-08 | — | — | CN | disclosed |
| US-8158787-B2 | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2128141-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | DPYD, TYMP, TST | KDM4E 4378/4885GAA 2959/4885NPC1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.